However, tumor-targeted radiotherapy, which may generate in situ vaccination following induction of immunogenic cell death of cancer cells, shows a broader TCR repertoire and increases antitumor efficacy to an anti-CTLA-4 antibody [13, 14]. The gene discussed is CTLA4; the disease is cancer.